The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Meiji Seika Pharma Pins High Hopes on Schizophrenia Drug Sycrest
Meiji Seika Pharma is gunning for a bigger slice of shares in the Japanese CNS market by boosting its profile in the schizophrenia sector with Sycrest (asenapine) it launched in Japan on May 26, President Daikichiro Kobayashi said. “The drug…
To read the full story
Related Article
- Meiji Plans Japan-Bound Generic Projection in India to Seek Cost Competitiveness
June 1, 2016
- 180 Billion Yen Sales in FY2017 Is “Quite Reachable”: Meiji Seika Pharma President
May 22, 2015
- Meiji Holdings Aims at Sales of 180 Billion Yen and 30% Overseas Sales Ratio in Pharma Business by FY2017
May 19, 2015
BUSINESS
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
- JCR Earns Japan Rights to DMD Drug from Italfarmaco
December 25, 2025
- Fujifilm Completes Major Biologics CDMO Plant in Toyama, Eyes 2027 Start-Up
December 25, 2025
- Alfresa’s Cell Resources Inks Partnership with Korea’s ENCell
December 25, 2025
- Aculys Rolls Out Spydia Nasal Spray in Japan
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…